At a glance
ClinicalIndex Comparison RecordN/ACompleted· 64 enrolled
Drug / intervention
cerebral embolic protection during TAVRdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cerebral Protection in Transcatheter Aortic Valve Replacement - The PROTEMBO C Trial
In Brief
A clinical study evaluating cerebral embolic protection during TAVR for Valvular Heart Disease. Completed, enrolled 64 participants across 8 sites in 3 countries.
Detailed Summary
The PROTEMBO C Trial is an international, multi-center, single arm, non-inferiority study of the safety and performance of using the ProtEmbo System for cerebral embolic protection in subjects with severe native aortic valve stenosis indicated for TAVR.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsValvular Heart Disease
CountriesGermany, Latvia, Poland
CollaboratorsAvania
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartJul 2020
First PostedNov 2020
Primary CompletionNov 2022
TodayJul 2026
First PostedNov 6, 2020
Enrollment StartJul 31, 2020
Primary CompletionNov 23, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.7 years ago
Interventions
cerebral embolic protection during TAVRdevice
The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.